EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-β-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria

Koji Takemoto iD, Ryo Nakayama, Koichi Fujimoto, Yumiko Suzuki, Yukiko Takarabe, Masako Honsho, Sachiko Kitahara, Yoshihiko Noguchi, Hidehito Matsui, Tomoyasu Hirose, Yukihiro Asami, Jun Hidaka und 2 weitere

Antimicrobial Agents and Chemotherapy · 06.05.2024

DOI: 10.1128/aac.01602-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 06.05.2024. Verfasst von Koji Takemoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Drug Research Division, Sumitomo Pharma Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: Meropenem, Microbial Sensitivity Tests, Anti-Bacterial Agents, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KSP-1007 is a novel bicyclic boronate-based broad-spectrum β-lactamase inhibitor and is being developed in combination with meropenem (MEM) for the treatment of infections caused by carbapenem-resistant Gram-negative bacteria, a global health concern, and here, we describe its characteristics. KSP-1007 exhibited low apparent inhibition constant ( K i app ) values against all classes of β-lactamase, including imipenemase types and oxacillinase types from Acinetobacter baumannii . Against 207 Enterobacterales and 55 A . baumannii , including carbapenemase producers, KSP-1007 at fixed concentrations of 4, 8, and 16 µg/mL dose-dependently potentiated the in vitro activity of MEM in broth microdilution MIC testing. The MIC 90 of MEM/KSP-1007 at 8 µg/mL against Enterobacterales was lower than those of MEM/vaborbactam, ceftazidime/avibactam, imipenem/relebactam, and colistin and similar to those of aztreonam/avibactam, cefiderocol, and tigecycline. The in vitro activity of MEM/KSP-1007 at ≥4 µg/mL against Enterobacterales harboring metallo-β-lactamase was superior to that of cefepime/taniborbactam. MEM/KSP-1007 showed excellent activity against Escherichia coli with PBP3 mutations and New Delhi metallo-β-lactamase compared to aztreonam/avibactam, cefepime/taniborbactam, and cefiderocol. MEM/KSP-1007 at 8 µg/mL showed greater efficacy against A. baumannii than these comparators except for cefiderocol, tigecycline, and colistin. A 2-fold reduction in MEM MIC against 96 Pseudomonas aeruginosa was observed in combination with KSP-1007. MEM/KSP-1007 demonstrated bactericidal activity against carbapenemase-producing Enterobacterales , A. baumannii , and P. aeruginosa based on minimum bactericidal concentration/MIC ratios of ≤4. KSP-1007 enhanced the in vivo activity of MEM against carbapenemase-producing Enterobacterales , A. baumannii , and P. aeruginosa in murine systemic, complicated urinary tract, and thigh infection models. Collectively, MEM/KSP-1007 has a good profile for treating carbapenem-resistant Gram-negative bacterial infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-Lactamase InhibitorsAcinetobacter baumanniibeta-LactamasesAzabicyclo CompoundsAnimalsMiceBoronic AcidsGram-Negative BacteriaColistinCarbapenemsBacterial ProteinsDrug CombinationsCephalosporinsCarbapenem-Resistant EnterobacteriaceaePseudomonas aeruginosaCeftazidime

Stichwörter der Autor:innen

antibiotic resistancebeta-lactamasescarbapenems

Substanzen

MeropenemAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesAzabicyclo CompoundsBoronic AcidscarbapenemaseColistinCarbapenemsavibactam, ceftazidime drug combination

Autor:innen und Institutionen

  • Drug Research Division, Sumitomo Pharma Co., Ltd., Osaka, Japan.
  • Ōmura Satoshi Memorial Institute, Kitasato University, Tokyo, Japan.
  • Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan.

ORCID-Profile: Koji Takemoto

Förderung

  • Japan Agency for Medical Research and Development (AMED)

Zitieren

APA

Takemoto, K., Nakayama, R., Fujimoto, K., Suzuki, Y., Takarabe, Y., Honsho, M., Kitahara, S., Noguchi, Y., Matsui, H., Hirose, T., Asami, Y., Hidaka, J., Sunazuka, T., & Hanaki, H. (2024). In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-β-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01602-23

Vancouver

Takemoto K, Nakayama R, Fujimoto K, Suzuki Y, Takarabe Y, Honsho M, et al. In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-β-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01602-23

BibTeX
@article{Takemoto2024,
  author = {Takemoto, Koji and Nakayama, Ryo and Fujimoto, Koichi and Suzuki, Yumiko and Takarabe, Yukiko and Honsho, Masako and Kitahara, Sachiko and Noguchi, Yoshihiko and Matsui, Hidehito and Hirose, Tomoyasu and Asami, Yukihiro and Hidaka, Jun and Sunazuka, Toshiaki and Hanaki, Hideaki},
  title = {In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-β-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01602-23}
}
Kostenlos starten →